Electrocatalytic Reduction of Disulfide Bonds in Antibodies

19 February 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


In most FDA-approved antibody-drug conjugates, cysteines generated through reduction of the native interchain di-sulfide bonds in monoclonal antibodies (mAbs) are conjugated with maleimide-based cytotoxic payloads. Despite being key to efficiently producing well-defined conjugates, selective disulfide reduction strategies are severely underdevel-oped. Herein, we report a vitamin B12-catalyzed, electrochemically driven protocol that efficiently reduces disulfide bonds in various aqueous buffers and at a broad pH range. This robust and simple method is suitable for disulfide reduc-tions of substrates ranging from biologically relevant small molecules to large proteins. Finally, one-pot reduc-tion/conjugation of disulfide bonds in mAbs was achieved to access antibody conjugates.


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.